{"product_id":"vtrs-business-model-canvas","title":"Viatris Inc. (VTRS): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eGet a ready-made, research-based Business Model Canvas of Viatris Inc. that shows you how the company creates value through affordable medicines, a broad generic and specialty portfolio, and supply to about \u003cstrong\u003e1 billion\u003c\/strong\u003e patients across \u003cstrong\u003e165 countries\u003c\/strong\u003e. You'll see the core partnerships, activities, resources, channels, customer segments, revenue streams, and cost drivers behind its global manufacturing footprint of \u003cstrong\u003e27\u003c\/strong\u003e sites, plus the strategic focus on ophthalmology, dermatology, and gastroenterology, so you can use it as a practical study aid for essays, case studies, presentations, and business analysis.\u003c\/p\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$3.335 billion\u003c\/strong\u003e is the most important partnership-linked transaction in Viatris Inc.'s biosimilars strategy, because it reshaped the company's role from direct biosimilars operator into a partner with continuing commercial and equity exposure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eRelationship type\u003c\/td\u003e\n\u003ctd\u003eReal-life number or amount\u003c\/td\u003e\n\u003ctd\u003eBusiness impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiocon Biologics\u003c\/td\u003e\n\u003ctd\u003eBiosimilars transaction and commercial collaboration\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003e$3.335 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eConverted a business line into cash plus equity exposure\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiocon Biologics\u003c\/td\u003e\n\u003ctd\u003eCash consideration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProvided immediate liquidity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiocon Biologics\u003c\/td\u003e\n\u003ctd\u003eEquity consideration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.55%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eKept Viatris linked to future value creation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eRegulatory gatekeeper\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e approval pathway for U.S. launches\u003c\/td\u003e\n \u003ctd\u003eDetermines market entry timing and labeling\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePMDA\u003c\/td\u003e\n\u003ctd\u003eRegulatory gatekeeper\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e approval pathway for Japan launches\u003c\/td\u003e\n \u003ctd\u003eDetermines market entry timing in Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiocon Limited \/ Biocon Biologics\u003c\/strong\u003e is the most visible partnership in Viatris Inc.'s Business Model Canvas. The economics matter because the biosimilars transaction included \u003cstrong\u003e$2 billion\u003c\/strong\u003e in cash and a \u003cstrong\u003e12.55%\u003c\/strong\u003e equity stake, so Viatris did not just exit a business line; it kept a financial interest in the asset's future performance.\u003c\/p\u003e\n\n\u003cp\u003eThis matters for the canvas because key partnerships are not only about operations. They also affect capital allocation, risk transfer, and future cash flows. A cash component improves balance-sheet flexibility, while an equity stake preserves upside if the biosimilars platform grows.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.335 billion\u003c\/strong\u003e total consideration tied to the biosimilars transaction\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$2 billion\u003c\/strong\u003e cash that could support debt reduction, dividends, or reinvestment\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e12.55%\u003c\/strong\u003e continuing equity interest that ties Viatris to long-term value creation\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic work, this partnership is useful because it shows how a pharmaceutical company can use a divestiture-plus-equity structure instead of a simple sale. That structure changes the business model from direct ownership to shared economic exposure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDA and PMDA regulatory bodies\u003c\/strong\u003e are not commercial partners, but they function as essential external dependencies. Viatris Inc. cannot launch many products in the U.S. without FDA approval, and it cannot launch in Japan without PMDA approval. In the business model canvas, these bodies shape access to revenue, because regulatory timing can move launches by quarters or years.\u003c\/p\u003e\n\n\u003cp\u003eThe practical value of these relationships is measurable in time and cost, even when no single dollar amount is disclosed. Every approval cycle affects development spending, inventory planning, and expected cash flow timing. In plain English, the regulator decides when a future cash flow can start.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFDA\u003c\/strong\u003e controls U.S. market entry for prescription medicines and biosimilars\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003ePMDA\u003c\/strong\u003e controls Japanese review and approval pathways\u003c\/li\u003e\n \u003cli\u003eApproval timing affects launch timing, revenue timing, and patent-exposure timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor a case study, these regulatory partnerships matter because they are repeated relationships, not one-time events. Viatris Inc. must keep quality systems, pharmacovigilance, manufacturing controls, and dossier preparation aligned with both agencies across multiple products.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal manufacturing and supply chain partners\u003c\/strong\u003e matter because Viatris Inc. runs a complex multi-country supply network for active pharmaceutical ingredients, finished-dose manufacturing, packaging, and distribution support. In this model, partners are needed to reduce single-site risk, support local-market supply, and keep medicines available when demand shifts.\u003c\/p\u003e\n\n\u003cp\u003eSupply chain partnerships matter financially because they influence gross margin. Gross margin is revenue after direct product costs. If a company has to use more external manufacturing, expedited freight, or dual sourcing, product cost rises and margin falls.\u003c\/p\u003e\n\n\u003cp\u003eIn the pharmaceutical industry, this relationship is especially important for:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eActive pharmaceutical ingredient sourcing\u003c\/li\u003e\n \u003cli\u003eContract manufacturing of selected dosage forms\u003c\/li\u003e\n \u003cli\u003ePackaging and serialization support\u003c\/li\u003e\n\u003cli\u003eCold-chain and temperature-controlled logistics\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe strategic value is resilience. A diversified manufacturing footprint lowers the chance that one facility outage will interrupt supply across multiple markets. That matters because even short interruptions can affect revenue, customer trust, and regulatory standing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHealthcare distributors and pharmacy networks\u003c\/strong\u003e are the main commercial link between Viatris Inc. and patients in many markets. These channels include wholesalers, retail pharmacy chains, hospital systems, and group purchasing organizations. They matter because a medicine that is approved and manufactured still cannot generate revenue until it reaches the dispensing network.\u003c\/p\u003e\n\n\u003cp\u003eFor academic analysis, these partnerships are important because they shape bargaining power. Large distributors can press for lower prices, faster fill rates, and broader product availability. That can support volume, but it can also compress net selling prices.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eWholesalers move product in large volume to downstream customers\u003c\/li\u003e\n \u003cli\u003eRetail pharmacy networks convert prescriptions into final sales\u003c\/li\u003e\n \u003cli\u003eHospitals and health systems drive demand for selected injectable and specialty products\u003c\/li\u003e\n \u003cli\u003ePurchasing groups influence contract terms and reimbursement access\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe key number to track here is not always a disclosed partnership fee. It is the spread between list price and net price, because distributor and pharmacy economics determine how much of the top-line sale reaches Viatris Inc. as net revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstitutional shareholders\u003c\/strong\u003e are a different kind of partnership because they are not operating partners, but they shape governance, capital discipline, and strategic pressure. In Viatris Inc.'s case, large institutions matter because they influence voting outcomes, board accountability, and expectations around buybacks, dividends, debt, and portfolio reshaping.\u003c\/p\u003e\n\n\u003cp\u003eInstitutional ownership also matters because pharmaceutical companies often depend on long-term capital to fund litigation, compliance, product launches, and restructuring. Large shareholders tend to focus on cash generation, leverage, and execution quality.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLarge asset managers can affect voting outcomes on directors and compensation\u003c\/li\u003e\n \u003cli\u003eLong-term holders can support strategic patience during restructuring\u003c\/li\u003e\n \u003cli\u003eActive managers can push for asset sales, margin expansion, or capital returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn business model terms, institutional shareholders do not deliver medicines or regulatory approvals, but they do shape the capital structure that supports them. That makes them a real key partnership layer for Viatris Inc., especially when the company is balancing debt, cash flow, and portfolio simplification.\u003c\/p\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$15.4 billion\u003c\/strong\u003e in 2023 net sales, \u003cstrong\u003e$5.9 billion\u003c\/strong\u003e in adjusted EBITDA, and \u003cstrong\u003e$2.9 billion\u003c\/strong\u003e in free cash flow show that Viatris Inc.'s key activities are built around volume manufacturing, regulatory execution, and cost control rather than high-margin innovation alone.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eBusiness purpose\u003c\/th\u003e\n\u003cth\u003eReal-life scale indicators\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelop and file generic and specialty medicines\u003c\/td\u003e\n \u003ctd\u003eBuild a pipeline of products that can win approvals, extend labels, and replace aging revenue streams\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e; global portfolio across generics and specialty medicines\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacture and supply medicines globally\u003c\/td\u003e\n \u003ctd\u003eKeep medicines available across many markets through a large manufacturing and supply network\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e; operations spanning multiple regions and markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecure regulatory approvals and label expansions\u003c\/td\u003e\n \u003ctd\u003eObtain marketing authorization and broaden approved uses for existing products\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e; regulatory filings across multiple jurisdictions\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOptimize portfolio and cut costs\u003c\/td\u003e\n\u003ctd\u003eShift capital toward higher-value products and reduce structural expenses\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e$5.9 billion\u003c\/strong\u003e adjusted EBITDA in 2023\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManage divestitures and facility rationalization\u003c\/td\u003e\n \u003ctd\u003eSell non-core assets and reduce manufacturing footprint where capacity is no longer needed\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e; continuing portfolio reshaping after the 2020 launch of Viatris Inc.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eDeveloping and filing generic and specialty medicines is the core production and growth task. In practice, this means preparing dossiers, stability data, bioequivalence work, and manufacturing documentation for regulators. For a company with a broad portfolio, the activity matters because each approval can add revenue without the long development cycle of a new drug. Viatris Inc. uses this activity to support a portfolio that is commercially large and geographically broad, which lowers dependence on any single product.\u003c\/p\u003e\n\n\u003cp\u003eManufacturing and supply are just as important as product development. Medicines only create revenue when they can be produced reliably, released to quality standards, and shipped on time. For Viatris Inc., this is a global coordination task across active pharmaceutical ingredient sourcing, finished-dose production, quality testing, packaging, and distribution. In a business with \u003cstrong\u003e$15.4 billion\u003c\/strong\u003e in annual net sales, even small supply disruptions can affect revenue, working capital, and customer trust.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMaintain plant output for high-volume medicines\u003c\/li\u003e\n \u003cli\u003eBalance inventory against demand in multiple regions\u003c\/li\u003e\n \u003cli\u003eManage quality release so batches can be sold\u003c\/li\u003e\n \u003cli\u003eReduce shipping delays that can interrupt hospital, retail, and government supply\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSecuring regulatory approvals and label expansions is a separate activity from manufacturing because a product can only be sold within the exact scope approved by regulators. Label expansion can add new dosage forms, age groups, indications, or geographies. That matters strategically because it can raise the value of an existing molecule without requiring a completely new product launch. For a company like Viatris Inc., this is a lower-cost way to extend the life of a medicine and protect revenue from erosion.\u003c\/p\u003e\n\n\u003cp\u003ePortfolio optimization and cost cutting are central to the economics of the business model. Viatris Inc. has to decide which products deserve investment, which products should be maintained with minimal spending, and which should be exited. The financial goal is to convert sales into cash efficiently. The reported \u003cstrong\u003e$5.9 billion\u003c\/strong\u003e in adjusted EBITDA in 2023 shows the importance of operating discipline, because EBITDA is earnings before interest, taxes, depreciation, and amortization, a measure that helps show operating profit before non-cash charges and financing structure.\u003c\/p\u003e\n\n\u003cp\u003eKey operating priorities in this area usually include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eReducing overlapping administrative and commercial costs\u003c\/li\u003e\n \u003cli\u003eFocusing capital on products with stronger returns\u003c\/li\u003e\n \u003cli\u003eImproving gross margin through procurement and manufacturing efficiency\u003c\/li\u003e\n \u003cli\u003eLowering SG\u0026amp;A, which means selling, general, and administrative costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eManaging divestitures and facility rationalization is a direct way to shrink complexity. A divestiture is the sale of a business or product line. Facility rationalization means closing, consolidating, or resizing plants and support sites. These actions matter because they can lower fixed costs, simplify supply chains, and release cash, but they can also create restructuring charges and execution risk. In a company focused on broad medicine access and margin discipline, this activity supports a leaner operating model.\u003c\/p\u003e\n\n\u003cp\u003eFor academic work, the most useful point is that Viatris Inc.'s key activities are not just manufacturing. They connect \u003cstrong\u003eregulatory execution\u003c\/strong\u003e, \u003cstrong\u003eglobal supply reliability\u003c\/strong\u003e, \u003cstrong\u003eportfolio decisions\u003c\/strong\u003e, and \u003cstrong\u003ecost discipline\u003c\/strong\u003e into one operating system. That is why the company can report large-scale cash generation while still depending on constant product filings, approvals, and manufacturing control.\u003c\/p\u003e\n\n\u003cp\u003eLate-stage operating priorities can be grouped like this:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D and filings:\u003c\/strong\u003e product dossiers, approvals, and label changes\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eSupply chain:\u003c\/strong\u003e production, quality, packaging, and distribution\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eCommercial continuity:\u003c\/strong\u003e keeping approved medicines in market\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eStructural change:\u003c\/strong\u003e divestitures, site closures, and cost reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese activities support a business that depends on scale, global reach, and cash conversion. They matter because a medicine portfolio only creates value if it can be approved, made, shipped, and kept profitable across multiple markets.\u003c\/p\u003e\n\u003ch2\u003eViatris Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e27\u003c\/strong\u003e-site global manufacturing footprint.\u003c\/p\u003e\n\u003cp\u003eCommercial reach across \u003cstrong\u003e165\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D pipeline assets in \u003cstrong\u003ePhase 3\u003c\/strong\u003e and \u003cstrong\u003eNDA\u003c\/strong\u003e status.\u003c\/p\u003e\n\u003cp\u003eGlobal centers in \u003cstrong\u003ePittsburgh\u003c\/strong\u003e, \u003cstrong\u003eShanghai\u003c\/strong\u003e, and \u003cstrong\u003eHyderabad\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eKey resource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness model role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e27\u003c\/strong\u003e sites\u003c\/td\u003e\n\u003ctd\u003eProduction scale, supply continuity, and geographic diversification\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial reach\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e165\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eMarket access, distribution breadth, and sales coverage\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment pipeline\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePhase 3\u003c\/strong\u003e and \u003cstrong\u003eNDA\u003c\/strong\u003e assets\u003c\/td\u003e\n \u003ctd\u003eFuture product flow and lifecycle support\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal centers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e centers\u003c\/td\u003e\n\u003ctd\u003eCoordination of strategy, operations, and development\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e27\u003c\/strong\u003e manufacturing sites matter because Viatris depends on scale, regulatory compliance, and multi-region supply. A wider footprint reduces dependence on any single plant and supports continuity when one location faces quality, logistics, or local disruption issues.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e27\u003c\/strong\u003e sites support multi-country production\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e165\u003c\/strong\u003e countries support broad product access\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e global centers support cross-border coordination\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003ePhase 3\u003c\/strong\u003e assets support late-stage development value\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eNDA\u003c\/strong\u003e assets support potential near-term regulatory filing activity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCommercial reach across \u003cstrong\u003e165\u003c\/strong\u003e countries is a core resource because it gives Viatris a wide route to market. In a business model canvas, this resource supports the channels and customer relationships blocks because a larger country footprint usually means more distributors, regulators, reimbursement systems, and sales execution points to manage.\u003c\/p\u003e\n\n\u003cp\u003eThe R\u0026amp;D pipeline is a resource even in a large off-patent and complex-generic business because \u003cstrong\u003ePhase 3\u003c\/strong\u003e is the late-stage human testing phase and \u003cstrong\u003eNDA\u003c\/strong\u003e is the New Drug Application stage. Those stages matter because they sit closest to possible commercial launch among development assets and can support future revenue replacement or expansion.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eR\u0026amp;D stage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMeaning\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePhase 3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLate-stage clinical testing\u003c\/td\u003e\n\u003ctd\u003eCloser to regulatory submission and potential commercialization\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eNDA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRegulatory filing stage\u003c\/td\u003e\n\u003ctd\u003eSignals a product is near a decision point for approval\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe centers in \u003cstrong\u003ePittsburgh\u003c\/strong\u003e, \u003cstrong\u003eShanghai\u003c\/strong\u003e, and \u003cstrong\u003eHyderabad\u003c\/strong\u003e matter because they concentrate management, science, and operating expertise in three major locations. That structure helps Viatris coordinate global manufacturing, development, and commercial execution across time zones and regions.\u003c\/p\u003e\n\n\u003cp\u003eStrong cash generation and liquidity are key resources because they fund working capital, capital spending, debt service, and development activity. In a capital-intensive healthcare business, cash generation matters because it gives the company room to keep manufacturing, quality systems, and pipeline work running without relying only on external financing.\u003c\/p\u003e\n\n\u003cp\u003eThe resource mix is strongest when these five items work together: \u003cstrong\u003e27\u003c\/strong\u003e sites for supply, \u003cstrong\u003e165\u003c\/strong\u003e countries for sales reach, \u003cstrong\u003ePhase 3\u003c\/strong\u003e and \u003cstrong\u003eNDA\u003c\/strong\u003e assets for future growth, \u003cstrong\u003e3\u003c\/strong\u003e global centers for coordination, and cash flow for funding and resilience.\u003c\/p\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eViatris Inc.\u003c\/strong\u003e positions its value proposition around large-scale access, a wide medicine portfolio, and a shift toward higher-growth specialty areas. The core customer promise is simple: supply medicines to patients across a very large global footprint while using a mix of established generics and selective specialty assets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eValue proposition\u003c\/th\u003e\n\u003cth\u003eReal-life metric or fact\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal access to medicines\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e1 billion patients\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eShows the scale of patient reach behind the company's access model\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational distribution\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e165 countries and territories\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eSupports broad access across developed and emerging markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth focus in specialty care\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e named focus areas: ophthalmology, dermatology, and gastroenterology\u003c\/td\u003e\n \u003ctd\u003eSignals where Viatris expects higher-growth product economics\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk-balanced innovation model\u003c\/td\u003e\n\u003ctd\u003eEmphasis on late-stage and commercialized assets instead of only early-stage R\u0026amp;D\u003c\/td\u003e\n \u003ctd\u003eReduces binary clinical trial risk compared with a pure biopharma model\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffordable medicines at global scale\u003c\/strong\u003e is the clearest part of the value proposition. Viatris sells medicines that are meant to be cheaper than many originator drugs, and it does so at a scale measured in \u003cstrong\u003eabout 1 billion patients\u003c\/strong\u003e. That matters because affordability only creates real value if the company can also distribute reliably across many markets. The company's reach across more than \u003cstrong\u003e165 countries and territories\u003c\/strong\u003e shows that this is not a local or regional model. It is built for high-volume access, which is important in academic analysis because scale can lower unit cost and widen patient access at the same time.\u003c\/p\u003e\n\n\u003cp\u003eThis affordability proposition matters to payers, governments, pharmacies, and hospital systems. It gives them a lower-cost sourcing option for medicines that are already widely needed. In business-model terms, Viatris captures value by selling at large volumes rather than relying only on high prices per unit. That is a different logic from many branded drug companies, where price per prescription does most of the work. Here, the value proposition depends on breadth, consistency, and procurement relevance.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAbout 1 billion patients\u003c\/strong\u003e indicate a large addressable base for essential medicines.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e165+ countries and territories\u003c\/strong\u003e show that the model depends on global regulatory and commercial execution.\u003c\/li\u003e\n \u003cli\u003eLow-cost access is strongest where buyers care about price, continuity, and availability at the same time.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad generic and specialty portfolio\u003c\/strong\u003e is the second major value proposition. Viatris does not depend on one product or one therapy area. Instead, it combines generics with specialty medicines, which gives it a wider customer base and more ways to serve different price points. In practical terms, generics support volume and access, while specialty products support differentiation and potentially better margins. That mix matters because it reduces dependence on any single product line and makes the company more resilient when one segment faces pricing pressure or patent loss.\u003c\/p\u003e\n\n\u003cp\u003eThe portfolio also supports cross-market reach. A broad set of medicines can serve retail pharmacies, hospitals, wholesalers, and public health systems. For academic work, this is important because it shows how a company can build strategic strength from product diversity rather than from one blockbuster drug. Viatris's model is not pure innovation and not pure commoditization. It sits between the two.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics support volume-based sales and market breadth.\u003c\/li\u003e\n \u003cli\u003eSpecialty medicines support differentiation and stronger pricing power.\u003c\/li\u003e\n \u003cli\u003eA mixed portfolio lowers concentration risk compared with a single-therapy company.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovation-led growth with lower early-stage risk\u003c\/strong\u003e is another part of the value proposition. Viatris can pursue growth through later-stage development, lifecycle management, and targeted specialty expansion without relying only on large, uncertain discovery programs. That matters because early-stage pharmaceutical R\u0026amp;D has high failure risk, long timelines, and heavy cash needs. A model weighted toward approved products and advanced-stage assets usually carries less scientific uncertainty than a company built around early discovery.\u003c\/p\u003e\n\n\u003cp\u003eThis does not mean the company has no innovation exposure. It means the innovation profile is more selective. For investors and researchers, that usually implies a different risk-return structure: less upside from a major first-in-class breakthrough, but also less downside from repeated clinical failures. In plain English, Viatris tries to grow by improving and expanding known commercial platforms rather than by betting everything on unproven science.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReliable supply to about 1 billion patients\u003c\/strong\u003e is a value proposition on its own. In medicines, supply reliability is not a side issue. If a product is unavailable, the patient and the buyer lose trust immediately. A company serving such a large patient base must manage manufacturing, quality control, sourcing, and distribution with discipline. That matters because a low-cost medicine has limited value if it cannot be delivered consistently.\u003c\/p\u003e\n\n\u003cp\u003eThe reliability message also supports institutional buying decisions. Health systems and distributors need predictable supply because stock-outs can interrupt therapy and raise replacement costs. For Viatris, this creates a non-price advantage: even when multiple suppliers compete on cost, the one that can deliver consistently has a stronger commercial position. In academic terms, this is a mix of operational capability and customer trust.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSupply-related value point\u003c\/th\u003e\n\u003cth\u003eBusiness impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e1 billion patients\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eRequires large-scale manufacturing and distribution discipline\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e165+ countries and territories\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003eRequires regulatory, logistics, and quality consistency across markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAffordable medicines\u003c\/td\u003e\n\u003ctd\u003ePricing advantage only works if supply stays reliable\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigher-growth focus in ophthalmology, dermatology, and gastroenterology\u003c\/strong\u003e gives Viatris a more selective specialty direction. These three areas matter because they can support stronger growth than mature generics markets, especially when products have clear clinical use and recurring demand. The company's strategy in these areas reflects a move toward more differentiated medicines where brand, clinical profile, and physician adoption matter more than low-cost manufacturing alone.\u003c\/p\u003e\n\n\u003cp\u003eIn strategic terms, this focus helps balance the portfolio. Ophthalmology can bring recurring treatment demand. Dermatology can offer broad outpatient use. Gastroenterology can support chronic or repeated treatment patterns. Together, these areas can improve the company's growth profile without requiring a full shift away from generics. For academic analysis, this is a useful example of a hybrid business model: one part access-driven, one part specialty-driven.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eOphthalmology\u003c\/strong\u003e supports specialty differentiation and repeated patient use.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eDermatology\u003c\/strong\u003e supports outpatient demand and broad physician adoption.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eGastroenterology\u003c\/strong\u003e supports chronic-care demand and recurring use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eViatris's value proposition works because it combines \u003cstrong\u003escale\u003c\/strong\u003e, \u003cstrong\u003ebreadth\u003c\/strong\u003e, \u003cstrong\u003ereliability\u003c\/strong\u003e, and \u003cstrong\u003eselective specialty growth\u003c\/strong\u003e. The company is not selling a single promise. It is selling access, continuity, and a portfolio that can serve both price-sensitive and growth-oriented markets.\u003c\/p\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eViatris Inc.\u003c\/strong\u003e builds customer relationships through long-term supply contracts, tender-based selling, compliance-heavy product support, and regular engagement with healthcare providers, while also keeping investor attention on cash returns through dividends and buybacks.\u003c\/p\u003e\n\n\u003cp\u003eIts customer model is not built on brand loyalty in the consumer sense. It is built on continuity, regulatory reliability, delivery performance, and price discipline across large institutional buyers, health systems, governments, distributors, and prescribers.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHow it works\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term supply agreements\u003c\/td\u003e\n\u003ctd\u003eMulti-period contracts with large buyers for steady product supply\u003c\/td\u003e\n \u003ctd\u003eSupports volume stability and lowers demand volatility\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulated product support\u003c\/td\u003e\n\u003ctd\u003eQuality, labeling, pharmacovigilance, and compliance support\u003c\/td\u003e\n \u003ctd\u003eRequired for market access and repeat purchasing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTender and contract-based selling\u003c\/td\u003e\n\u003ctd\u003eBids and negotiated contracts with institutions and public buyers\u003c\/td\u003e\n \u003ctd\u003eDrives access to large-volume accounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare provider engagement\u003c\/td\u003e\n\u003ctd\u003eMedical information and product-use support for clinicians\u003c\/td\u003e\n \u003ctd\u003eSupports prescribing and product adoption\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor return focus\u003c\/td\u003e\n\u003ctd\u003eDividend payments and share repurchases\u003c\/td\u003e\n\u003ctd\u003eShapes shareholder relationship and capital allocation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eLong-term supply agreements are central to Viatris because many of its products are sold into channels that need dependable replenishment. In this model, the customer values supply certainty, regulatory compliance, and price discipline as much as the product itself. For an academic paper, this shows that the relationship is transactional on price but relational on execution.\u003c\/p\u003e\n\n\u003cp\u003eThe company's customer base is broad and institutional. That usually means the buying decision sits with procurement teams, not end users. In practice, this makes service levels, fill rates, quality assurance, and on-time delivery part of the relationship. A failure in one of these areas can affect contract renewal, formulary access, or tender eligibility.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLarge-volume customers often buy through fixed terms rather than open-ended spot purchases.\u003c\/li\u003e\n \u003cli\u003eSupply reliability matters because many healthcare products cannot be substituted quickly.\u003c\/li\u003e\n \u003cli\u003eContract renewal depends on price, quality record, and regulatory compliance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegulated, compliance-driven product support is a core relationship feature because Viatris operates in pharmaceuticals, where the customer relationship continues after the sale. Customers need product information, safety updates, adverse event handling, quality documentation, and support for audits or inspections. These are not optional service layers. They are part of the license to operate.\u003c\/p\u003e\n\n\u003cp\u003eThis relationship model also reduces room for informal selling. A healthcare customer will often require documentation that confirms manufacturing standards, traceability, and consistency. That means trust is built through repeat compliance performance, not marketing claims. For research work, this is important because it shows how regulation shapes the structure of customer relationships in pharma.\u003c\/p\u003e\n\n\u003cp\u003eTender and contract-based institutional selling is another major channel. In this setup, the customer is often a hospital system, government purchaser, pharmacy benefit entity, or group purchasing organization. The buying process is formal and price sensitive. The company wins business by meeting technical specifications, regulatory requirements, and commercial terms inside a bidding process.\u003c\/p\u003e\n\n\u003cp\u003eThe table below maps the relationship logic to the commercial outcome.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer group\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship form\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCommercial effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers and distributors\u003c\/td\u003e\n\u003ctd\u003eSupply contracts and replenishment agreements\u003c\/td\u003e\n \u003ctd\u003eSupports steady product flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and health systems\u003c\/td\u003e\n\u003ctd\u003eTenders and formulary-based contracts\u003c\/td\u003e\n\u003ctd\u003eDrives large-volume placements\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments and public purchasers\u003c\/td\u003e\n\u003ctd\u003eBid-based procurement\u003c\/td\u003e\n\u003ctd\u003eCreates price pressure but can lock in volume\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare providers\u003c\/td\u003e\n\u003ctd\u003eMedical and product-use engagement\u003c\/td\u003e\n\u003ctd\u003eSupports confidence in product selection\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOngoing engagement with healthcare providers matters because physicians, pharmacists, and hospital decision-makers influence which products get used. Even when the final purchase is made by a procurement team, clinical acceptance still matters. Viatris must maintain medical communication that supports appropriate use, safety, and continuity of care.\u003c\/p\u003e\n\n\u003cp\u003eThis type of relationship is usually less visible than consumer marketing, but it is more important in pharmaceuticals. If providers trust the product quality, dosing consistency, and safety profile, that lowers switching friction. In academic analysis, this is a good example of how business-to-business healthcare selling depends on clinical credibility as well as pricing.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eProvider trust affects formulary placement.\u003c\/li\u003e\n \u003cli\u003eClinical support affects adoption after a procurement award.\u003c\/li\u003e\n \u003cli\u003eSafety and quality communication affects retention of institutional accounts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eViatris also maintains a relationship with shareholders through capital returns. The company paid a quarterly dividend of \u003cstrong\u003e$0.12\u003c\/strong\u003e per share. On an annualized basis, that equals \u003cstrong\u003e$0.48\u003c\/strong\u003e per share if the rate is held for four quarters.\u003c\/p\u003e\n\n\u003cp\u003eThat matters because investor expectations are tied to cash generation, debt discipline, and capital allocation. In plain English, dividends are cash paid directly to shareholders, while buybacks reduce the number of shares outstanding if management repurchases stock. Both are ways of returning money to owners instead of keeping all cash inside the business.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$0.12\u003c\/strong\u003e quarterly dividend per share\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$0.48\u003c\/strong\u003e annualized dividend per share\u003c\/li\u003e\n \u003cli\u003eShare repurchases support per-share earnings if done below intrinsic value\u003c\/li\u003e\n \u003cli\u003eDividend continuity signals cash flow confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor a Business Model Canvas analysis, Viatris' customer relationships are best described as high-compliance, low-emotion, contract-led relationships. The company does not rely on frequent consumer interaction. It relies on repeat institutional buying, regulatory trust, and operational consistency.\u003c\/p\u003e\n\n\u003cp\u003eThat means relationship strength depends less on brand storytelling and more on measurable performance: supply continuity, contract wins, regulatory standing, and cash returns to shareholders.\u003c\/p\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eViatris Inc. uses a mix of direct commercial selling, third-party distribution, public-sector tendering, and regulatory filing routes to move products into more than \u003cstrong\u003e165\u003c\/strong\u003e countries and territories. Its channel design reflects a portfolio that includes branded, generic, and complex products, with a reported workforce of about \u003cstrong\u003e38,000\u003c\/strong\u003e employees and 2024 net sales of \u003cstrong\u003e$14.7 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect global commercial sales force\u003c\/strong\u003e is the main channel for products that need account management, medical education, and local market access work. This channel matters because prescription medicines often depend on physician adoption, formulary placement, and hospital procurement decisions, not just price. Viatris uses in-country commercial teams in its key markets to support brand retention, product launches, contract renewals, and tender execution. For academic analysis, this channel shows how a pharmaceutical company turns scientific products into recurring revenue through relationship-based selling rather than retail advertising alone.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel element\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect global commercial sales force\u003c\/td\u003e\n\u003ctd\u003eMarket access, account management, medical engagement\u003c\/td\u003e\n \u003ctd\u003eSupports prescription volume, formulary access, and contract retention\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital, pharmacy, and wholesaler networks\u003c\/td\u003e\n \u003ctd\u003ePhysical product distribution and inventory flow\u003c\/td\u003e\n \u003ctd\u003eMoves medicines through the supply chain to patients and providers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment and payer tenders\u003c\/td\u003e\n\u003ctd\u003eBid-based procurement for public buyers and insurers\u003c\/td\u003e\n \u003ctd\u003eDrives large-volume sales in price-sensitive markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline investor and corporate communications\u003c\/td\u003e\n \u003ctd\u003eDisclosure, guidance, earnings access, governance communication\u003c\/td\u003e\n \u003ctd\u003eShapes capital-market confidence and analyst coverage\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory submission channels\u003c\/td\u003e\n\u003ctd\u003eApproval, labeling, lifecycle management, and market entry\u003c\/td\u003e\n \u003ctd\u003eRequired before products can be sold in many markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospital, pharmacy, and wholesaler networks\u003c\/strong\u003e are the core physical distribution channels for most of Viatris Inc.'s portfolio. These networks matter because medicines usually move from manufacturer to wholesaler, then to hospital, retail pharmacy, clinic, or government channel before reaching patients. In practical terms, this means channel performance depends on service levels, fill rates, cold-chain handling where relevant, inventory planning, and country-specific distributor relationships. For generic and off-patent products, these networks are especially important because availability and contract execution often decide market share more than brand advertising.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eHospital networks support inpatient and specialist use cases.\u003c\/li\u003e\n \u003cli\u003ePharmacy networks support community dispensing and repeat prescription volume.\u003c\/li\u003e\n \u003cli\u003eWholesalers support scale, reach, and inventory positioning across geographies.\u003c\/li\u003e\n \u003cli\u003eDistributor relationships reduce the need for Viatris Inc. to build full direct infrastructure in every market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGovernment and payer tenders\u003c\/strong\u003e are a major channel in public health systems and large insurance-led markets. This channel is important because the winning bid can lock in volume for a defined period, but usually at a lower unit price. For Viatris Inc., tender participation fits a portfolio that includes high-volume medicines where access and scale matter. Tender channels reward manufacturing reliability, regulatory readiness, pricing discipline, and local compliance. They also increase concentration risk because losing a tender can quickly reduce sales in that market.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eTender channel feature\u003c\/th\u003e\n\u003cth\u003eTypical effect on Viatris Inc.\u003c\/th\u003e\n\u003cth\u003eStrategic implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice-based competition\u003c\/td\u003e\n\u003ctd\u003eLower unit margins\u003c\/td\u003e\n\u003ctd\u003eRequires cost control and manufacturing efficiency\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge-volume awards\u003c\/td\u003e\n\u003ctd\u003eHigher shipment concentration\u003c\/td\u003e\n\u003ctd\u003eCan improve plant utilization and planning\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFixed contract terms\u003c\/td\u003e\n\u003ctd\u003eMore predictable demand during contract life\u003c\/td\u003e\n \u003ctd\u003eSupports inventory and production scheduling\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualification requirements\u003c\/td\u003e\n\u003ctd\u003eHigher compliance burden\u003c\/td\u003e\n\u003ctd\u003eRewards regulatory and quality capability\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOnline investor and corporate communications\u003c\/strong\u003e are a channel to capital markets, not to patients. Viatris Inc. uses its website, earnings materials, SEC filings, and investor relations communications to distribute quarterly and annual results, debt updates, governance information, and strategic disclosures. This channel matters because a company with 2024 net sales of \u003cstrong\u003e$14.7 billion\u003c\/strong\u003e and complex global operations depends on clear disclosure to support liquidity, valuation, and credit confidence. In academic work, this channel is useful when analyzing transparency, agency risk, and how management explains business performance to shareholders and lenders.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eQuarterly earnings releases communicate sales, margins, cash flow, and guidance updates.\u003c\/li\u003e\n \u003cli\u003eAnnual reports and proxy materials communicate strategy, risk, board governance, and compensation.\u003c\/li\u003e\n \u003cli\u003eInvestor presentations help explain portfolio mix, debt structure, and capital allocation.\u003c\/li\u003e\n \u003cli\u003eCorporate websites support product, compliance, and sustainability disclosures.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory submission channels\u003c\/strong\u003e are the formal paths through which Viatris Inc. seeks product approval, label changes, renewals, and manufacturing site approvals. These channels are critical because a pharmaceutical product cannot be marketed in many countries without regulator review. The company must file dossiers with agencies such as the FDA, EMA, and other national regulators, often using region-specific formats and legal requirements. This channel affects time to market, portfolio breadth, and lifecycle value. It also creates a gatekeeping function: without regulatory clearance, no downstream channel can generate revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRegulatory channel\u003c\/th\u003e\n\u003cth\u003eBusiness purpose\u003c\/th\u003e\n\u003cth\u003eChannel impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew product filings\u003c\/td\u003e\n\u003ctd\u003eObtain market authorization\u003c\/td\u003e\n\u003ctd\u003eEnables initial launch and revenue generation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVariations and amendments\u003c\/td\u003e\n\u003ctd\u003eChange labels, sites, or formulations\u003c\/td\u003e\n\u003ctd\u003eSupports lifecycle management and supply continuity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewals\u003c\/td\u003e\n\u003ctd\u003eMaintain existing approvals\u003c\/td\u003e\n\u003ctd\u003ePrevents interruption of sales in mature markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality and manufacturing submissions\u003c\/td\u003e\n\u003ctd\u003eDocument compliance and site readiness\u003c\/td\u003e\n\u003ctd\u003eProtects distribution continuity and product supply\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eViatris Inc.'s channel structure is tied to scale and geography. With products sold in more than \u003cstrong\u003e165\u003c\/strong\u003e countries and territories, the company needs a layered model: direct teams for strategic accounts, distributors and wholesalers for reach, tenders for public volume, digital disclosure for capital markets, and regulatory filings for legal market access. That mix is what makes the channel side of the Business Model Canvas important for a company with global supply chains and a broad pharmaceutical portfolio.\u003c\/p\u003e\n\u003ch2\u003eViatris Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eViatris Inc. sells to five main customer groups:\u003c\/strong\u003e patients who need lower-cost medicines, specialty patients in ophthalmology, dermatology, and gastrointestinal care, institutional buyers such as hospitals and pharmacies, payers and government health programs, and international buyers in Greater China and Emerging Markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer segment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhat matters in this segment\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eNumber or factual anchor\u003c\/strong\u003e\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients needing affordable generic medicines\u003c\/td\u003e\n \u003ctd\u003ePrice, access, and continued supply of chronic and acute therapies\u003c\/td\u003e\n \u003ctd\u003eGenerics are the largest prescription volume category in the U.S.; about \u003cstrong\u003e90%\u003c\/strong\u003e of prescriptions filled are generic medicines\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty patients in ophthalmology, dermatology, and GI\u003c\/td\u003e\n \u003ctd\u003eBranded or differentiated therapies with higher clinical complexity\u003c\/td\u003e\n \u003ctd\u003eGlobal disease burden includes about \u003cstrong\u003e2.2 billion\u003c\/strong\u003e people with vision impairment or blindness, about \u003cstrong\u003e125 million\u003c\/strong\u003e people with psoriasis, and about \u003cstrong\u003e10%\u003c\/strong\u003e to \u003cstrong\u003e20%\u003c\/strong\u003e of people worldwide with irritable bowel syndrome\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare systems, hospitals, and pharmacies\u003c\/td\u003e\n \u003ctd\u003eReliable supply, formulary access, and procurement economics\u003c\/td\u003e\n \u003ctd\u003eU.S. pharmacies dispense billions of prescriptions each year; hospital and chain pharmacy buyers often negotiate at scale\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers and government health programs\u003c\/td\u003e\n\u003ctd\u003eBudget control, substitution, rebates, and reimbursement discipline\u003c\/td\u003e\n \u003ctd\u003ePublic programs and insurers fund a large share of prescription spending in the U.S. and Europe\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational markets, especially Greater China and Emerging Markets\u003c\/td\u003e\n \u003ctd\u003eLocalized pricing, registration, channel access, and volume growth\u003c\/td\u003e\n \u003ctd\u003eViatris operates in more than \u003cstrong\u003e165\u003c\/strong\u003e countries and territories\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatients needing affordable generic medicines\u003c\/strong\u003e are the core volume segment. This group includes people treating hypertension, diabetes, cholesterol, infection, pain, and other high-prevalence conditions. The business logic is simple: if a medicine is off-patent, stable, and widely prescribed, demand is driven by affordability and availability rather than premium branding. This segment matters because it gives Viatris scale. In the U.S., about \u003cstrong\u003e90%\u003c\/strong\u003e of prescriptions are filled with generic medicines, which means the segment is tied to prescription volume rather than high unit pricing.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eChronic therapy patients who refill monthly or quarterly\u003c\/li\u003e\n \u003cli\u003eAcute-care patients needing short treatment cycles\u003c\/li\u003e\n \u003cli\u003ePatients in cost-sensitive markets where out-of-pocket spending is high\u003c\/li\u003e\n \u003cli\u003eBuyers who switch quickly when price or supply changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty patients in ophthalmology, dermatology, and GI\u003c\/strong\u003e are a smaller but strategically important segment. These patients usually need disease-specific therapies with stronger clinical differentiation, tighter prescribing control, and more specialist involvement. In ophthalmology, the addressable need is large because about \u003cstrong\u003e2.2 billion\u003c\/strong\u003e people worldwide live with vision impairment or blindness. In dermatology, about \u003cstrong\u003e125 million\u003c\/strong\u003e people worldwide live with psoriasis. In GI, irritable bowel syndrome affects about \u003cstrong\u003e10%\u003c\/strong\u003e to \u003cstrong\u003e20%\u003c\/strong\u003e of people globally. These figures matter because they show why specialty demand can remain durable even when generic pricing is under pressure.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eOphthalmology patients managed by eye-care specialists\u003c\/li\u003e\n \u003cli\u003eDermatology patients with chronic inflammatory skin disease\u003c\/li\u003e\n \u003cli\u003eGI patients needing longer treatment plans and physician follow-up\u003c\/li\u003e\n \u003cli\u003ePatients who are more dependent on access, diagnosis, and adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHealthcare systems, hospitals, and pharmacies\u003c\/strong\u003e are institutional customers that decide access, stocking, and substitution. These buyers do not purchase medicine for personal use; they buy at scale and care about supply continuity, service levels, and contract terms. This segment matters because it shapes which products are available on shelves and on hospital formularies. A single preferred listing can produce large volume, while delisting can cut access fast. For Viatris, this segment is especially important for broad, high-volume products that fit procurement rules and pharmacy purchasing models.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eInstitutional buyer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary buying criterion\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eBusiness impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eClinical use, supply reliability, contract terms\u003c\/td\u003e\n \u003ctd\u003eFormulary access can drive large inpatient and discharge volume\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacies\u003c\/td\u003e\n\u003ctd\u003eAvailability, substitution, reimbursement spread\u003c\/td\u003e\n \u003ctd\u003eHigh prescription turnover creates recurring demand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth systems\u003c\/td\u003e\n\u003ctd\u003eTotal cost of care, standardization, supplier consistency\u003c\/td\u003e\n \u003ctd\u003eSystemwide contracts can lock in volume across many sites\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayers and government health programs\u003c\/strong\u003e are a separate customer segment because they control reimbursement, formulary access, and budget rules. This includes private insurers, pharmacy benefit managers, national health systems, and public programs. Their main objective is to reduce unit cost while keeping clinical coverage intact. That makes them central to Viatris' business model, especially for generic medicines and selected specialty products. This segment matters because a product can have strong clinical demand but weak commercial performance if reimbursement is poor or if preferred placement goes to a cheaper rival.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePrivate insurers seeking lower drug spend\u003c\/li\u003e\n \u003cli\u003ePharmacy benefit managers managing U.S. formularies\u003c\/li\u003e\n \u003cli\u003eGovernment health programs controlling public budgets\u003c\/li\u003e\n \u003cli\u003eNational health systems negotiating price and access\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational markets, especially Greater China and Emerging Markets\u003c\/strong\u003e, are important because medicine demand grows with population, diagnosis rates, and access to formal healthcare. Viatris operates in more than \u003cstrong\u003e165\u003c\/strong\u003e countries and territories, so a large part of its customer base sits outside the U.S. Greater China and Emerging Markets tend to be more price-sensitive than mature markets, which strengthens the fit for a company with a broad generics portfolio and selective specialty products. This segment matters because it gives Viatris geographic diversification and exposure to patient populations that are still expanding access to modern medicines.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePatients in urban and secondary-care markets\u003c\/li\u003e\n \u003cli\u003ePublic and private hospital systems\u003c\/li\u003e\n\u003cli\u003eLocal distributors and pharmacy chains\u003c\/li\u003e\n\u003cli\u003eGovernment procurement programs and reimbursement systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eGeographic segment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGreater China\u003c\/td\u003e\n\u003ctd\u003eLarge patient base, pricing pressure, and registration barriers\u003c\/td\u003e\n \u003ctd\u003eNeeds local channel access and regulatory execution\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging Markets\u003c\/td\u003e\n\u003ctd\u003eGrowth in diagnosis and medicine access\u003c\/td\u003e\n\u003ctd\u003eTypically more price-sensitive than U.S. or Western Europe\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeveloped markets\u003c\/td\u003e\n\u003ctd\u003eVolume scale and reimbursement discipline\u003c\/td\u003e\n \u003ctd\u003eGeneric substitution and payer control drive demand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$14.7 billion\u003c\/strong\u003e in net sales, \u003cstrong\u003e$6.7 billion\u003c\/strong\u003e in cost of sales, and \u003cstrong\u003e$656 million\u003c\/strong\u003e in research and development expense were the main operating-cost anchors in the most recently reported annual period available in Viatris Inc. filings.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCost item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePeriod\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$656 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring and other charges\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$173 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e$6.7 billion\u003c\/strong\u003e of cost of sales reflects the largest direct cost bucket in the model. For a global generic and branded medicines company, this category usually includes active pharmaceutical ingredients, finished-dose manufacturing, packaging, quality control, freight, warehousing, and third-party manufacturing. The size of this line matters because even small changes in plant yield, procurement prices, or freight rates can move gross margin by tens or hundreds of millions of dollars.\u003c\/p\u003e\n\n\u003cp\u003eManufacturing and supply chain costs also sit inside cost of sales through inventory and production efficiency. When a company sells across many markets, the cost base is shaped by factory utilization, transfer pricing, and the number of regulated production sites needed to keep products supplied in multiple jurisdictions. For Viatris Inc., this is a structural cost because the portfolio is broad and highly distributed.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.7 billion\u003c\/strong\u003e cost of sales\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$14.7 billion\u003c\/strong\u003e net sales\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e45%\u003c\/strong\u003e cost of sales as a share of net sales, based on \u003cstrong\u003e$6.7 billion\u003c\/strong\u003e divided by \u003cstrong\u003e$14.7 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResearch and development spending was \u003cstrong\u003e$656 million\u003c\/strong\u003e. In a business model canvas, this is not as large as the manufacturing base, but it still matters because generic substitution, complex generics, biosimilars, and product life-cycle management all depend on development work, formulation studies, and bioequivalence testing. R\u0026amp;D also supports retention of product approvals in regulated markets.\u003c\/p\u003e\n\n\u003cp\u003eUsing the reported numbers, R\u0026amp;D represented \u003cstrong\u003e4.5%\u003c\/strong\u003e of net sales, based on \u003cstrong\u003e$656 million\u003c\/strong\u003e divided by \u003cstrong\u003e$14.7 billion\u003c\/strong\u003e. That ratio is a useful academic measure because it shows how much of the cost structure is tied to future product support rather than current production.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eR\u0026amp;D measure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eShare of net sales\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$656 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRegulatory filings and approvals add cost through dossier preparation, stability studies, inspections, quality-system maintenance, and country-by-country submissions. These costs are usually embedded in R\u0026amp;D, quality, and legal-compliance spending rather than shown as a separate line item. For a multi-market pharmaceutical company, the cost is recurring because product registrations have to be maintained, renewed, and updated when labels, manufacturing sites, or formulations change.\u003c\/p\u003e\n\n\u003cp\u003eFacility closures, downsizing, and remediation appear in restructuring and other charges. Viatris Inc. reported \u003cstrong\u003e$173 million\u003c\/strong\u003e of restructuring and other charges in 2024. These charges matter because they capture the cash and non-cash cost of changing the operating footprint, reducing headcount, closing sites, and fixing environmental or manufacturing issues tied to older assets.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$173 million\u003c\/strong\u003e restructuring and other charges\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$3.3 billion\u003c\/strong\u003e selling, general and administrative expense\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e22.4%\u003c\/strong\u003e selling, general and administrative expense as a share of net sales, based on \u003cstrong\u003e$3.3 billion\u003c\/strong\u003e divided by \u003cstrong\u003e$14.7 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLitigation and settlement payments are part of the cost structure because a pharmaceutical company with a large historical product portfolio carries ongoing legal exposure. These costs can include defense spending, accruals, settlements, and insurance recoveries. Where a company does not present a separate annual figure in the same line item, the cost still affects operating income, cash flow, and balance-sheet reserves.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCost structure component\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eReported amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAnalytical point\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and supply chain\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLargest direct cost base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$656 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4.5%\u003c\/strong\u003e of net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory work\u003c\/td\u003e\n\u003ctd\u003eIncluded in operating expenses\u003c\/td\u003e\n\u003ctd\u003eEmbedded in compliance and development spending\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility closures and remediation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$173 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRestructuring and other charges\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitigation and settlements\u003c\/td\u003e\n\u003ctd\u003eIncluded in operating expenses and accruals\u003c\/td\u003e\n \u003ctd\u003eCash and reserve impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe cost structure is therefore dominated by production scale, global distribution, compliance-heavy development, restructuring, and legal exposure. The most visible quantified elements are \u003cstrong\u003e$6.7 billion\u003c\/strong\u003e in cost of sales, \u003cstrong\u003e$656 million\u003c\/strong\u003e in R\u0026amp;D, \u003cstrong\u003e$3.3 billion\u003c\/strong\u003e in SG\u0026amp;A, and \u003cstrong\u003e$173 million\u003c\/strong\u003e in restructuring and other charges.\u003c\/p\u003e\u003ch2\u003eViatris Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$15.4 billion\u003c\/strong\u003e in 2023 net sales is the main revenue anchor for Viatris Inc., and the company's commercial footprint spans \u003cstrong\u003e165 countries and territories\u003c\/strong\u003e. Revenue comes from a mix of generic prescription medicines, specialty and branded medicines, and launches across multiple international markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness relevance\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal net sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$15.4 billion\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003ctd\u003eShows the scale of the full portfolio and the size of the company's cash-generating base\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e165 countries and territories\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003eShows how revenue is spread across many markets instead of relying on one country\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue mix\u003c\/td\u003e\n\u003ctd\u003eGeneric prescription medicines, specialty medicines, branded medicines, launches, and international sales\u003c\/td\u003e\n \u003ctd\u003eReduces dependence on a single product type and supports steadier sales\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eGeneric prescription medicine sales are the volume engine of the revenue model. In this type of business, sales usually come from high unit counts and lower prices than branded medicines, so the key driver is market access and scale rather than premium pricing. For Viatris Inc., this matters because generic products can generate recurring revenue across many countries and can keep cash flow coming in even when individual products face pricing pressure.\u003c\/p\u003e\n\n\u003cp\u003eSpecialty and branded medicine sales contribute a different kind of revenue: lower volume, higher value per prescription, and more protection from direct price competition. This stream matters because it can lift margins and reduce pressure from commoditized generic pricing. In a business model canvas, this is the part of the model that helps balance the lower-margin generic base with higher-value products.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eGeneric prescription medicines: volume-driven sales\u003c\/li\u003e\n \u003cli\u003eSpecialty medicines: higher-value prescription sales\u003c\/li\u003e\n \u003cli\u003eBranded medicines: premium-priced prescription revenue\u003c\/li\u003e\n \u003cli\u003eNew launches: incremental sales from recently approved products\u003c\/li\u003e\n \u003cli\u003eInternational sales: revenue across \u003cstrong\u003e165 countries and territories\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNew product launches and approvals are important because they replace revenue that can be lost as older products mature. Each new approval adds another product that can be sold through existing commercial channels, which lowers the cost of reaching the market compared with building a new business from scratch. For an academic analysis, this is the clearest link between research, regulation, and revenue growth.\u003c\/p\u003e\n\n\u003cp\u003eInternational sales across \u003cstrong\u003e165 countries and territories\u003c\/strong\u003e make the company's revenue model globally diversified. This reduces concentration risk and gives the company more than one demand base. It also means revenue can come from multiple reimbursement systems, regulatory regimes, and price environments, which affects both growth and margin structure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eGeographic area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream role\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life figure\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGreater China\u003c\/td\u003e\n\u003ctd\u003ePortfolio growth area\u003c\/td\u003e\n\u003ctd\u003eIncluded in the company's \u003cstrong\u003e165-country\u003c\/strong\u003e commercial footprint\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging Markets\u003c\/td\u003e\n\u003ctd\u003ePortfolio growth area\u003c\/td\u003e\n\u003ctd\u003eIncluded in the company's \u003cstrong\u003e165-country\u003c\/strong\u003e commercial footprint\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal business\u003c\/td\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$15.4 billion\u003c\/strong\u003e in 2023 net sales\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePortfolio growth in Greater China and Emerging Markets matters because these regions can add new demand sources to the revenue base. In practical terms, growth in these markets helps offset slower sales in more mature markets and supports broader product lifecycle value. For a student paper, this is a useful example of how geography can be part of revenue strategy, not just market expansion.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$15.4 billion\u003c\/strong\u003e net sales in 2023\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e165 countries and territories\u003c\/strong\u003e served\u003c\/li\u003e\n \u003cli\u003eMultiple revenue sources across generic, specialty, branded, and launched products\u003c\/li\u003e\n \u003cli\u003eGrowth opportunities tied to Greater China and Emerging Markets\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601628197013,"sku":"vtrs-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vtrs-business-model-canvas.png?v=1740229080","url":"https:\/\/dcf-model.com\/fr\/products\/vtrs-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}